Last reviewed · How we verify
NCT05006534
Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma
trial in Relapsed Non Hodgkin Lymphoma in 40 participants. Completed in 29 June 2021.
29 June 2021
Quick facts
| Lead sponsor | National Taiwan University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 June 2020 |
| Primary completion | 29 June 2021 |
| Estimated completion | 29 June 2021 |
| Sites | 1 location across Taiwan |
Conditions studied
- Relapsed Non Hodgkin Lymphoma — all drugs for Relapsed Non Hodgkin Lymphoma →
- Refractory Lymphoma — all drugs for Refractory Lymphoma →
Sponsor
National Taiwan University Hospital
Who can join
20 and older, any sex, with Relapsed Non Hodgkin Lymphoma or Refractory Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study enrolled patients with relapsed or refractory diffuse large B cell lymphoma treated with polatuzumab vedotin-based chemoimmunotherapies. Patients were allowed to use chemotherapy regimens other than Rituximab and Bendamustine and transplantation following polatuzumab vedotin was also allowed.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
Wang YW, Tsai XC, Hou HA, Tien FM, et al · · 2022 · cited 18× · PMID 34766217 · DOI 10.1007/s00277-021-04711-9 -
Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review).
Lu J, Ding J, Liu Z, Chen T. · · 2022 · cited 14× · PMID 34981814 · DOI 10.3892/ijo.2022.5302
Verify or expand the search:
- PubMed search for NCT05006534
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Relapsed Non Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT05260957 — CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma · Phase 2 · recruiting
- NCT03774654 — CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) · Phase 1 · active not recruiting
Other National Taiwan University Hospital trials
Trials by the same sponsor.
- NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
- NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
- NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
- NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
- NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05006534 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
- Last refreshed: 16 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05006534.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing